Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 13, 2026
Can Bank of America (BAC) Stock Reach $65?

Can Bank of America (BAC) Stock Reach $65?

Key Takeaways

  • Target in focus: The $65 level represents a meaningful psychological and technical milestone for Bank of America Corporation (BAC), sitting roughly 11% above recent closing prices near $58.30 and above the stock's 52-week high of $60.83.
  • Strongest bullish factors: Robust net interest income growth, surging investment banking fees (up 43% year-over-year), improving operational efficiency, and a healthy capital position with a CET1 ratio of 11.6% support the case for continued upside.
  • Biggest risks: A potential economic slowdown, credit normalization with rising loan delinquencies, regulatory uncertainty, and the possibility of interest rate cuts that could compress net interest margins represent the primary obstacles.
  • Key levels to watch: The $60.83 area marks the current 52-week high and immediate resistance. A convincing breakout above $60 would open the path toward $65. On the downside, $50 represents a critical psychological and technical support zone.
  • Bottom line: Reaching $65 is a realistic but non-trivial objective that would likely require sustained earnings momentum, supportive macroeconomic conditions, and continued capital return to shareholders through buybacks and dividends.

Why $65 Is the Level Investors Are Watching

As Bank of America trades in the upper $50s, the $65 price target has emerged as a widely discussed objective among retail and institutional investors alike. The level sits comfortably above the stock's recent 52-week high of $60.83 and aligns with the upper range of Wall Street analyst price targets, which currently cluster between $58 and $70. Reaching $65 would represent a gain of roughly 11% from recent levels and would signal a decisive breakout from the trading range the stock has occupied in recent months.

Current Market Position

Bank of America commands a market capitalization of approximately $414 billion, making it one of the largest financial institutions in the United States. The stock carries a trailing price-to-earnings (P/E) ratio of roughly 14.6 and a forward P/E near 13.2, suggesting that earnings growth is expected to continue. The price-to-book ratio of approximately 1.5 reflects a premium valuation relative to tangible book value, which is typical for well-capitalized large banks with strong franchise value. The company pays a quarterly dividend of $0.28 per share and has been actively repurchasing shares—$5.3 billion in buybacks were executed during the third quarter alone.

What Could Drive BAC Toward $65

Several fundamental tailwinds support the case for higher prices. Net interest income (NII)—the difference between what the bank earns on loans and pays on deposits—remains a powerful earnings driver. Management has guided for 5% to 7% NII growth in fiscal 2026, citing mid-single-digit loan growth, ongoing repricing of fixed-rate assets, and favorable deposit repricing dynamics. Some analysts believe NII growth could approach 7% to 7.5% under optimistic conditions.

Beyond NII, non-interest income has been a standout performer. Investment banking fees surged 43% year-over-year in the most recent quarter, driven by increased M&A activity and capital markets transactions. Trading revenue also exceeded expectations, and the bank's efficiency ratio improved to approximately 61.4%—about 140 basis points better than consensus estimates. An efficiency ratio measures how much a bank spends to generate each dollar of revenue; a lower number indicates better cost control.

Capital return remains another catalyst. With a CET1 ratio of 11.6%, Bank of America sits comfortably above its 10% regulatory minimum, providing ample capacity for continued share repurchases and dividend increases. The combination of earnings growth and a shrinking share count creates a favorable setup for earnings per share (EPS) expansion. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Analyst Sentiment and Price Targets

Wall Street maintains a broadly constructive view of BAC. The consensus rating among 28 analysts is a "Moderate Buy," with roughly 23 buy ratings and 5 hold ratings. The average 12-month price target stands near $58, but several prominent firms hold targets well above that level. Morgan Stanley maintains an Overweight rating with a target of $68 to $70. Citigroup carries a Buy rating and a $62 target. TD Cowen raised its target to $61–$64 following the third-quarter earnings beat, while Barclays, Keefe Bruyette & Woods, and Goldman Sachs all maintain targets in the $58 to $59 range. The highest target on the Street sits at $73.50, while the lowest rests at roughly $34.

The dispersion in analyst targets reflects genuine uncertainty about the macroeconomic trajectory, interest rate path, and credit cycle. Targets above $60 generally assume a soft-landing economic scenario with manageable credit costs and sustained NII growth.

Obstacles That Could Prevent the Move

The path to $65 is not without significant hurdles. Credit quality remains the foremost concern for bank investors. While net charge-offs and delinquency rates have shown signs of stabilization, any deterioration in the economic backdrop—particularly in commercial real estate or consumer credit—could trigger reserve builds that pressure earnings. Even modest credit normalization could offset the benefits of NII growth.

Interest rate uncertainty represents another critical variable. Bank of America benefits from higher rates through improved NII, but aggressive rate cuts by the Federal Reserve would compress net interest margins and reduce the earnings tailwind that has supported the stock's recovery. The market's shifting expectations around Federal Reserve policy create an unpredictable backdrop for bank valuations.

Additionally, regulatory developments and capital requirements remain a persistent overhang. Any move toward stricter capital rules could limit the pace of share buybacks and temper investor enthusiasm for the sector.

Technical Landscape

From a technical perspective, the $60.83 level—the 52-week high—represents the immediate hurdle. A sustained move above $60 would confirm bullish momentum and establish a higher trading range. The $65 target aligns with a measured move projection based on the stock's recovery from the mid-$40s to the $60 area. On the downside, the $50 region has served as a reliable support zone, reinforced by the 200-day moving average. As long as BAC holds above $50, the broader uptrend remains intact, though the stock's elevated beta of 1.34 means it will likely amplify both advances and declines in the broader market.

AI Daily Buy/Sell Signals

Navigating the crosscurrents that influence Bank of America's stock price requires timely and data-driven decision-making. In my research process, AI Daily Buy/Sell Signals from Tickeron leverage artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical patterns, and AI-driven analysis. These signals help traders identify emerging opportunities, manage existing positions, and detect shifts in market trends without manually sifting through complex data. For investors tracking whether BAC can build momentum toward higher price targets, integrating AI-powered signal analysis into a broader research process can provide an additional layer of actionable insight.

Final Assessment

The question of whether Bank of America can reach $65 is best framed in terms of conditions rather than certainties. The $65 target appears realistic over a 12- to 18-month horizon if several factors align: net interest income continues its projected growth trajectory, credit quality remains manageable, the Federal Reserve avoids aggressive rate cuts, and the investment banking recovery sustains its momentum. The vigorous share repurchase program adds an additional tailwind that could accelerate per-share value creation. However, investors should recognize that bank stocks carry inherent cyclical risk. Any meaningful economic downturn, spike in credit losses, or adverse regulatory shift could keep $65 out of reach. Monitoring quarterly NII trends, credit metrics, and management guidance will be essential for assessing whether the fundamental foundation exists to support a move into the mid-$60s.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BAC

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


Momentum Indicator for BAC turns positive, indicating new upward trend

BAC saw its Momentum Indicator move above the 0 level on July 30, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 76 similar instances where the indicator turned positive. In of the 76 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BAC advanced for three days, in of 345 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 275 cases where BAC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for BAC moved out of overbought territory on July 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 47 similar instances where the indicator moved out of overbought territory. In of the 47 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Moving Average Convergence Divergence Histogram (MACD) for BAC turned negative on July 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BAC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BAC broke above its upper Bollinger Band on July 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. BAC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 20, placing this stock slightly worse than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.596) is normal, around the industry mean (1.949). P/E Ratio (14.550) is within average values for comparable stocks, (16.293). Projected Growth (PEG Ratio) (1.073) is also within normal values, averaging (1.624). Dividend Yield (0.018) settles around the average of (0.025) among similar stocks. P/S Ratio (3.965) is also within normal values, averaging (4.347).

Notable companies

The most notable companies in this group are JPMorgan Chase & Co (NYSE:JPM), Bank of America Corp (NYSE:BAC), HSBC Holdings PLC (NYSE:HSBC), Wells Fargo & Co (NYSE:WFC), Citigroup (NYSE:C), Barclays PLC (NYSE:BCS).

Industry description

Major banks are among the biggest companies in the world, often times with global reach and market capitalizations in the multi-billions. Large banks often have multiple arms spanning different disciplines, from deposits, to investment banking, to wealth management and insurance. The biggest banks often have key competitive advantages over smaller players in the industry in terms of brand recognition, cost of capital, and efficiency. Think J.P. Morgan, Bank of America, Wells Fargo, and Citigroup.

Market Cap

The average market capitalization across the Major Banks Industry is 216.73B. The market cap for tickers in the group ranges from 1.04M to 947.12B. JPM holds the highest valuation in this group at 947.12B. The lowest valued company is BACRP at 1.04M.

High and low price notable news

The average weekly price growth across all stocks in the Major Banks Industry was 1%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 17%. SAN experienced the highest price growth at 4%, while HSBC experienced the biggest fall at -4%.

Volume

The average weekly volume growth across all stocks in the Major Banks Industry was -16%. For the same stocks of the Industry, the average monthly volume growth was -9% and the average quarterly volume growth was -45%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 68
P/E Growth Rating: 29
Price Growth Rating: 39
SMR Rating: 8
Profit Risk Rating: 19
Seasonality Score: -22 (-100 ... +100)
View a ticker or compare two or three
BAC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a major bank

Industry MajorBanks

Profile
Details
Industry
Major Banks
Address
100 North Tryon Street
Phone
+1 704 386-5681
Employees
213000
Web
https://www.bankofamerica.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.